Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B

We read with great interest the recent article published in Journal of Hepatology by Papatheodoridis and his colleagues,1 which was designed to compare the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB) receiving entecavir (ETV) or tenofovir disoproxil fumarate (TDF) treatment. After an average follow-up of 7.1 ± 3.0 years, the authors indicated that the risk of HCC, rates of virological remission, HBsAg loss, and liver transplantation or death during ETV or TDF treatment were similar in CHB patients with or without cirrhosis.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research